Akorn, Inc.
Overview
Akorn, Inc. is a specialty pharmaceutical company that specializes in the development, manufacture, and marketing of generic and branded prescription pharmaceuticals as well as animal health products. Since becoming private, Akorn continues to focus on its core business of providing high-quality and cost-effective pharmaceutical solutions.
Therapeutic areas
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- recall — Class II2023-06-07
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.